Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01 Read More
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA™) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 Read More
Investor Relations Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up Read More
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates Read More
